HUTCHMED (China) (HCM) EBITDA (2015 - 2021)

HUTCHMED (China) (HCM) posted quarterly EBITDA of -$62.8 million for Q4 2021, down 127.61% quarter-over-quarter from $227.3 million in Q1 2021.

HUTCHMED (China) (HCM) EBITDA (2015 - 2021) Analysis & Trends

HUTCHMED (China) (HCM) has reported EBITDA for 6 consecutive years, with -$62.8 million the latest figure, recorded in Q4 2021.

In Q4 2021, EBITDA changed N/A year-over-year to -$62.8 million; the TTM figure through Dec 2021 stood at $381.1 million (changed N/A YoY), while the FY2025 annual figure was $102.8 million, up 335.3% from the prior year.
EBITDA fell to -$62.8 million in Q4 2021 per HCM's latest filing, from $227.3 million in the prior quarter.
Across five years, EBITDA topped out at $227.3 million in Q1 2021 and bottomed at -$161.1 million in Q4 2018.
Historically, EBITDA has averaged $11.8 million across 4 years, with a median of -$5.1 million in 2018.
Annual changes were most pronounced in 2019 — EBITDA sank 343.04% — and 2020, when it soared 292.37%.
HUTCHMED (China)'s EBITDA stood at -$161.1 million in 2018, then jumped by 76.14% to -$38.4 million in 2019, then surged by 295.36% to $75.1 million in 2020, then sank by 183.58% to -$62.8 million in 2021.
Business Quant data shows HCM's EBITDA at -$62.8 million in Q4 2021, $227.3 million in Q1 2021, and $75.1 million in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA (Qtr)
1	Haleon	43.65 Bn	42.68 Bn	-	-
2	Teva Pharmaceutical Industries	43.09 Bn	39.44 Bn	2.15 Bn	-231.00 Mn
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn	837.00 Mn
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	1.26 Bn
5	United Therapeutics	22.11 Bn	19.45 Bn	683.80 Mn	330.80 Mn
6	Viatris	18.77 Bn	17.88 Bn	1.46 Bn	6.30 Mn
7	Neurocrine Biosciences	15.62 Bn	15.23 Bn	935.80 Mn	151.50 Mn
8	Elanco Animal Health	12.07 Bn	11.54 Bn	798.00 Mn	248.00 Mn
9	Dr Reddys Laboratories	10.09 Bn	9.93 Bn	-	-
10	HUTCHMED (China)	2.17 Bn	2.17 Bn	-	-

Download Data